BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.71M | -53.47M | -88.88M | -123.82M | -145.93M |
| Total Depreciation and Amortization | 3.05M | 3.04M | 3.01M | 2.57M | 2.68M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 129.70M | 125.47M | 121.13M | 123.37M | 124.30M |
| Change in Net Operating Assets | -80.22M | -100.89M | -87.28M | -57.85M | -64.92M |
| Cash from Operations | 16.82M | -25.85M | -52.02M | -55.73M | -83.87M |
| Capital Expenditure | -1.06M | -1.03M | -1.12M | -1.00M | -1.93M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.56M | 51.96M | 53.72M | 7.33M | 22.88M |
| Cash from Investing | 82.51M | 50.93M | 52.59M | 6.32M | 20.95M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -77.68M | -1.83M | -1.70M | -2.51M | -1.96M |
| Issuance of Common Stock | 7.92M | 4.76M | 4.06M | 4.22M | 3.62M |
| Repurchase of Common Stock | -581.00K | -581.00K | -581.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.56M | -6.54M | -7.54M | -6.62M | -6.62M |
| Cash from Financing | -75.90M | -4.18M | -5.76M | -4.91M | -4.96M |
| Foreign Exchange rate Adjustments | 1.36M | -145.00K | -936.00K | 890.00K | 292.00K |
| Miscellaneous Cash Flow Adjustments | -15.06M | -- | -- | -- | -- |
| Net Change in Cash | 9.72M | 20.75M | -6.12M | -53.43M | -67.58M |